

29 March 2017

OBJ executes Collaboration Agreement with multi-national partner for BodyGuard

OBJ Limited (ASX: OBJ) has executed a Collaboration Agreement with an international manufacturing and distribution partner, initially focused on the commercial development of OBJ's BodyGuard technology. The partner is a well-renowned manufacturer and distributor of industrial adhesive tapes for the electronics, automotive, health care, medical devices, packaging and construction industries.

In addition to the commercial development of BodyGuard, the agreement will contain provisions for various outcomes from the collaboration including granting the partner first right of refusal to manufacture the BodyGuard product range. The partner will also have the non-exclusive right to distribute the BodyGuard product range in certain markets once it is fully commercialised.

OBJ will contribute its knowledge and expertise in formulation and claims support development, while the partner will contribute manufacturing, production engineering, distribution and packaging expertise.

The partnering corporation is one of the largest adhesive companies in the world, with sales in excess of US\$7 billion and more than 100 manufacturing centres globally. It produces transdermal drug patches, medical devices, medical materials, taping products, kinesiology and sports tapes.

"It is the partner's vast experience in the manufacture of the world's leading kinesiology tape products that first attracted us to this potential working relationship," said Glyn Denison, OBJ's Non-Executive Chairman.

"Establishing a high-volume, low-cost manufacturing capability is a major objective for BodyGuard as it allows for the development of various formulations required by distributors. The establishment of this collaboration agreement with such a reputable company is a major step forward in the last stage of BodyGuard's development program, that being a commercial end product that can be economically manufactured. The potential to encompass distribution in the same agreement is an excellent outcome for OBJ."

The collaboration agreement will also lead to OBJ introducing its micro-array technology for possible integration within the partner's existing product range.

OBJ's partners and customers will benefit from the best and most cost-effective production technologies, while the partner can explore the value-added potential of OBJ's technologies across its broad product range.

The collaboration will cover all aspects of mass production of the BodyGuard range in an appropriate high-quality, low-cost environment. It will also cover various studies designed to optimise the alternative formulations and consumer responses.

Directors

Mr Glyn Denison
Mr Jeffrey Edwards
Dr Chris Quirk

Company Secretary

Mr John Palermo

Registered Office:

284 Oxford Street
Leederville
Western Australia 6007
Tel: +61 8 9443 3011
Fax: +61 8 9443 9960
www.obj.com.au
ABN: 72 056 482 636

29 March 2017

The partnering company will draw support for the project from its various global manufacturing centres to ensure the manufacturability of BodyGuard.

About OBJ

OBJ develops proprietary magnetic micro-array drug delivery and product enhancement technologies for the pharmaceutical, healthcare and consumer goods sectors. OBJ partners companies in the design and development of next generation products using physical science rather than chemistry to provide new levels of product performance without the cost of reformulation or new ingredient approvals.

OBJ offers a portfolio of proprietary technologies and supports partners by providing IP-protected market exclusivity, expertise in magnetic array design, feasibility and efficacy and claims testing, engineering and production.

About OBJ's technologies

OBJ has developed a platform of physical enhancement technologies based on low-cost magnetic micro-arrays that influence the movement and penetration through the skin of drugs, active ingredients and formulations at the molecular level.

Complex 3-D array and moving magnetic fields have the ability to repulse certain molecules to enhance diffusion and to alter the permeability of certain biological and non-biological targets.

OBJ develops low cost micro-array film technology that utilise diamagnetic repulsion, induced permeation and energy redirection to offer a new way of managing the speed, depth of penetration and delivery of active ingredients in a wide range of pharmaceutical and consumer products.

Forward-looking statements

This announcement contains certain "forward-looking statements" concerning OBJ. Where OBJ expresses or implies an expectation or belief as to future events or results, such expectation or belief is expressed in good faith and believed to have a reasonable basis.

Forward-looking statements provided in this announcement are based on assumptions and contingencies which are subject to change without notice. Such forward-looking statements including statements regarding intentions, planned events and potential results are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance.

There can be no assurance that actual outcomes will not differ materially from these forward-looking statements, and there are risks associated with OBJ and the industry which may affect the accuracy of the forward-looking statements. OBJ does not undertake any obligation to release publicly any revisions to any forward looking statement to reflect events or circumstances after the date of this announcement or to reflect the occurrence of unanticipated events, except as may be required under applicable securities laws.

Directors

Mr Glyn Denison
Mr Jeffrey Edwards
Dr Chris Quirk

Company Secretary

Mr John Palermo

Registered Office:

284 Oxford Street
Leederville
Western Australia 6007
Tel: +61 8 9443 3011
Fax: +61 8 9443 9960
www.obj.com.au
ABN: 72 056 482 636

For personal use only



OBJ RELEASE

29 March 2017

For more information:

Matthew Wright

matt@nwrcommunications.com.au

Phone: +61 451 896 420

Directors

Mr Glyn Denison
Mr Jeffrey Edwards
Dr Chris Quirk

Company Secretary

Mr John Palermo

Registered Office:

**284 Oxford Street
Leederville
Western Australia 6007**
Tel: +61 8 9443 3011
Fax: +61 8 9443 9960
www.obj.com.au
ABN: 72 056 482 636

For personal use only